Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209201 | 0.87 | SMO (0.49) | SMONR3C1 | |
| SCHEMBL6208913 | 0.87 | SMO (0.44) | SMOMAPTCYP11B2NR3C1 | |
| SCHEMBL6209292 | 0.84 | PGR (0.41) | SMONR3C1 | |
| SCHEMBL6208280 | 0.83 | NOTUM (0.46) | MAPTRAB9A | |
| SCHEMBL6208380 | 0.76 | SMO (0.41) | SMOMAPTCYP11B2NR3C1MAPK1 | |
| SCHEMBL6209189 | 0.75 | CYP11B2 (0.53) | SMOCYP11B2NR3C1MAPK8MAPK9 | |
| SCHEMBL6210556 | 0.74 | NR3C1 (0.47) | SMONR3C1 | |
| SCHEMBL6208856 | 0.74 | CYP11B2 (0.49) | SMOMAPTCYP11B2KMT2AMAPK1 | |
| SCHEMBL6211940 | 0.72 | NR3C1 (0.39) | SMONR3C1 | |
| SCHEMBL6205298 | 0.72 | CA12 (0.44) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501833-B1 | N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6900201-B2 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1501833-A1 | N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040010141-A1 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003091258-A1 | N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010141-A1 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, MMP8, MMP2 | SMO 836/4885MAPT 4657/4885CYP11B2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.